Hematology Frontier

To promote innovation in China’s cell and immunotherapy fields, facilitate in-depth exchange on key scientific issues, share the latest clinical research progress, and advance global collaboration and clinical translation, the…

We are pleased to share a featured interview from the Cellular Therapy and Immunotherapy Conference 2025 (CTI 2025) in Hangzhou, conducted in collaboration with Hematology Frontier. In this in-depth discussion,…

On November 2, 2025, Professors Michael R. Bishop, M.D. and Edmund Waller visited the Peking University Institute of Hematology for an academic exchange that included ward rounds, keynote lectures, and…

On November 2, 2025, Professor Michael R. Bishop, M.D. visited the Peking University Institute of Hematology for clinical rounds, a keynote lecture, and focused exchanges on the future of cellular…

To promote innovation in China’s cell therapy and immunotherapy fields, advance discussion of key scientific challenges, share the latest clinical research, and strengthen global collaboration and translational progress, the 2025 International Cell & Immunotherapy Congress (CTI 2025)—jointly organized by Zhejiang University, the International Academy for Clinical Hematology (IACH), the Zhejiang Immunology Society, and the Zhejiang Anti-Cancer Association—was held on November 13–16, 2025 in Hangzhou. 

The 2024 China Expert Consensus on metagenomic next-generation sequencing (mNGS) in hematological disorders, published in Blood Science, offers the first national guidance on how mNGS should be applied to infection diagnosis in this highly vulnerable population. Because hematological diseases and their treatments cause profound immunosuppression, infections remain a major cause of morbidity and mortality. Traditional microbiological tests (CMTs) frequently produce delayed or negative results, especially after antibiotic exposure. mNGS, which enables broad, unbiased pathogen detection, has therefore become an essential complementary tool. 

Published in Blood Science in 2025, the study led by Zichang Shen examines the impact of central nervous system leukemia (CNSL) on outcomes after umbilical cord blood transplantation (UCBT). CNSL remains a difficult manifestation of acute leukemia…

Published in Blood Science in 2025, the study led by Zichang Shen examines the impact of central nervous system leukemia (CNSL) on outcomes after umbilical cord blood transplantation (UCBT). CNSL remains a difficult manifestation of acute leukemia because leukemic cells within the CNS can evade systemic chemotherapy and drive relapse. Although allogeneic transplantation is the most effective curative approach for high-risk disease, the influence of prior CNS involvement on post-transplant outcomes has remained uncertain. Shen and colleagues therefore evaluated how a history of CNSL affects long-term prognosis following UCBT. 

The commentary “Alpha-enolase promotes progression of acute myeloid leukemia via MAPK/ERK signaling pathway” by Zhang et al., published in Blood Science (2025), examines the clinical and biological significance of ENO1 in acute myeloid leukemia (AML). ENO1, a glycolytic enzyme with additional regulatory roles, has been implicated in several solid tumors, but its function in AML had not been fully clarified. Through integrated analyses of patient samples, functional assays, transcriptomics, and in vivo models, the authors demonstrate that ENO1 is overexpressed in AML and promotes disease progression mainly through MAPK/ERK pathway activation. 

The commentary “Unrelated Cord Blood as a Source of Stem Cells: Cryopreservation Damage Can Be Alleviated by Restoring Mitochondrial Function” by Norbert Claude Gorin, published in Blood Science (2025), highlights…